Functional precision medicine is reshaping oncology by integrating real-time drug testing, genomic data, and artificial intelligence to…
Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
- Update frequency
- every 5 days
- Episodes
- 347
- Years Active
- 2015 - 2025
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Guest: Jennifer Caudle, DO
Host: Patrick McGill, MD
Host: Patrick McGill, MD
Current cancer screening guidelines cover just five cancers—breast, lung, colon, prostate, and cervical—leaving many aggressive cance…
Fri 29 Aug 2025
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Evandro Bezerra, MD
Guest: Evandro Bezerra, MD
As CAR T-cell therapy advances, so does the complexity of adverse event monitoring. Due to evolving insights into acu…
Thu 28 Aug 2025
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Host: Brian P. McDonough, MD, FAAFP
Guest: Marie Wood, MD
Guest: Marie Wood, MD
Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are ch…
Mon 25 Aug 2025
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
Host: Brian P. McDonough, MD, FAAFP
Guest: Mylynda Massart, MD, PhD
Guest: Mylynda Massart, MD, PhD
Given its ability to identify universal cancer signals across multiple tumor types, multi-cancer early detection (MCE…
Mon 25 Aug 2025
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Host: Brian P. McDonough, MD, FAAFP
Guest: Marie Wood, MD
Guest: Marie Wood, MD
Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are ch…
Mon 25 Aug 2025
Improving CAR T Referrals for Large B-Cell Lymphoma: A Path to Better Collaboration
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Forat Lutfi, MD
Guest: Nilanjan Ghosh, MD, PhD
Guest: Forat Lutfi, MD
Guest: Nilanjan Ghosh, MD, PhD
For patients with relapsed/refractory large B-cell lymphoma, timely access to CAR T-ce…
Fri 22 Aug 2025
Improving CAR T Referrals for Large B-Cell Lymphoma: A Path to Better Collaboration
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Forat Lutfi, MD
Guest: Nilanjan Ghosh, MD, PhD
Guest: Forat Lutfi, MD
Guest: Nilanjan Ghosh, MD, PhD
For patients with relapsed/refractory large B-cell lymphoma, timely access to CAR T-ce…
Fri 22 Aug 2025
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Host: Ryan Quigley
Guest: Hallie Blevins, PhD.
Guest: Marlene Mimi Maeusli, PhD.
Guest: Hallie Blevins, PhD.
Guest: Marlene Mimi Maeusli, PhD.
With one in three eligible Americans still unscreened for colorectal cancer (CRC), there’s an urgent…
Tue 19 Aug 2025
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Host: Ryan Quigley
Guest: Hallie Blevins, PhD.
Guest: Marlene Mimi Maeusli, PhD.
Guest: Hallie Blevins, PhD.
Guest: Marlene Mimi Maeusli, PhD.
With one in three eligible Americans still unscreened for colorectal cancer (CRC), there’s an urgent…
Tue 19 Aug 2025
Redefining Cancer Care with Functional Precision Medicine
Host: Matt Birnholz, MD
Guest: Jim Foote, MBA
Guest: Jim Foote, MBA
Thu 14 Aug 2025
Redefining Cancer Care with Functional Precision Medicine
Host: Matt Birnholz, MD
Guest: Jim Foote, MBA
Guest: Jim Foote, MBA
Functional precision medicine is reshaping oncology by integrating real-time drug testing, genomic data, and artificial intelligence to…
Thu 14 Aug 2025
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sairah Ahmed, MD
Guest: Sairah Ahmed, MD
The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell t…
Thu 07 Aug 2025
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sairah Ahmed, MD
Guest: Sairah Ahmed, MD
The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell t…
Thu 07 Aug 2025
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hope S. Rugo, MD, FASCO
Guest: Hope S. Rugo, MD, FASCO
Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it’s also …
Wed 06 Aug 2025
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neil M. Iyengar, MD
Guest: Komal Jhaveri, MD, FACP
Guest: Neil M. Iyengar, MD
Guest: Komal Jhaveri, MD, FACP
The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent…
Wed 06 Aug 2025
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neil M. Iyengar, MD
Guest: Neil M. Iyengar, MD
Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limit…
Wed 06 Aug 2025
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hope S. Rugo, MD, FASCO
Guest: Hope S. Rugo, MD, FASCO
Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it’s also …
Wed 06 Aug 2025
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Guest: Brian Slomovitz, MD
Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise…
Wed 06 Aug 2025
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neil M. Iyengar, MD
Guest: Neil M. Iyengar, MD
Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limit…
Wed 06 Aug 2025
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neil M. Iyengar, MD
Guest: Komal Jhaveri, MD, FACP
Guest: Neil M. Iyengar, MD
Guest: Komal Jhaveri, MD, FACP
The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent…
Wed 06 Aug 2025
Disclaimer: The podcast and artwork embedded on this page are the property of ReachMD. This content is not affiliated with or endorsed by eachpod.com.